Jens Wiebe
Technische Universität München
39 Papers
109 Citations
Jens Wiebe is an academic researcher from Technische Universität München. The author has contributed to research in topics: Stent & Percutaneous coronary intervention. The author has an hindex of 9, co-authored 39 publications. Previous affiliations of Jens Wiebe include Ludwig Maximilian University of Munich.
Chat about Author
Papers
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Salvatore Cassese,Robert A. Byrne,Gjin Ndrepepa,Sebastian Kufner,Jens Wiebe,Janika Repp,Heribert Schunkert,Massimiliano Fusaro,Takeshi Kimura,Adnan Kastrati +9 more
TL;DR: Compared with everolimus-eluting metallic stents, everolitus-eluted bioresorbable vascular scaffolds had similar rates of repeat revascularisation at 1 year of follow-up, despite inferior mid-term angiographic performance, however, patients treated with a biores Orbital scaffold had an increased risk of subacute stent thrombosis.
376
Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis
Daniele Giacoppo,Roisin Colleran,Salvatore Cassese,Antonio H. Frangieh,Jens Wiebe,Michael Joner,Heribert Schunkert,Adnan Kastrati,Robert A. Byrne +8 more
TL;DR: Percutaneous coronary intervention and CABG show comparable safety in patients with LMCA stenosis and low to intermediate–complexity coronary artery disease, and repeat revascularization is more common after PCI.
117
10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents
Sebastian Kufner,Maximilian Ernst,Salvatore Cassese,Michael Joner,Katharina Mayer,Roisin Colleran,Tobias Koppara,Erion Xhepa,Tobias Koch,Jens Wiebe,Tareq Ibrahim,Massimiliano Fusaro,Karl-Ludwig Laugwitz,Heribert Schunkert,Adnan Kastrati,Robert A. Byrne,Isar-Test Investigators +16 more
TL;DR: At 10 years, there were no measurable differences in outcomes between patients treated with polymer-free versus durable polymer DES, and the incidence of stent thrombosis was low and comparable in both groups.
73
Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
Sebastian Kufner,Jonas Sorges,Julinda Mehilli,Salvatore Cassese,Janika Repp,Jens Wiebe,Raphaela Lohaus,Annalena Lahmann,Tobias Rheude,Tareq Ibrahim,Steffen Massberg,Karl L. Laugwitz,Adnan Kastrati,Robert A. Byrne,Isar-Test Investigators +14 more
TL;DR: Long-term outcomes of patients treated with polymer-free sirolimus- and probucol-Eluting stents compared with a new-generation durable polymer-based zotarolimus-eluting stent were similar, and rates of stent thrombosis were low and comparable in both treatment groups, with few events beyond 12 months.
64
Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.
Robert A. Byrne,Fernando Alfonso,Simon Schneider,Michael Maeng,Jens Wiebe,Evgeny Kretov,Christian Bradaric,Himanshu Rai,Javier Cuesta,Fernando Rivero,Petra Hoppmann,Jana Schlichtenmaier,Evald Høj Christiansen,Salvatore Cassese,Michael Joner,Heribert Schunkert,Karl-Ludwig Laugwitz,Adnan Kastrati +17 more
TL;DR: In patients undergoing PCI for acute MI BRS were non-inferior to EES for percentage diameter stenosis at angiographic follow-up, although the study was not powered to detect differences in clinical outcomes.
44